#United States #GSK #Lebanon #Adimab #Depemokimab

Adimab's Milestone with GSK: Depemokimab Approval

Adimab, LLC, a leader in antibody discovery and engineering, has warmly commended GSK plc for receiving new marketing approvals for its biologic product, depemokimab. Recently granted by the European Commission and China's National Medical Products Administration (NMPA), these approvals add to GSK's pantheon of successes in the United States, Japan, and the United Kingdom. Depemokimab isn’t just another drug; it’s the first ultra-long-acting biologic product approved for specific indications, representing a landmark achievement in biopharmaceutical innovation.

GSK developed depemokimab with a special focus on enhancing its half-life, allowing patients to receive doses merely twice a year. This revolutionizing approach was evidenced in several pivotal trials, clearly showcasing the drug's efficacy. To achieve these groundbreaking results, GSK adopted Adimab's proprietary yeast-based technology. This strategic move enabled GSK to manage antibody discovery, optimization, production, and characterization internally, giving them flexibility and control over the process.

Philip T. Chase, Adimab’s Chief Executive Officer, expressed his satisfaction with this notable collaboration, underscoring depemokimab as the inaugural product to emerge from their Platform Transfer partnerships. GSK was the first collaborator in this endeavor, solidifying a strong foundation in their business relationship. This achievement reflects the potential of Adimab’s technology in enabling pharmaceutical companies to develop pioneering therapeutic products.

Eric Krauland, Adimab’s President and Chief Scientific Officer, celebrated GSK's commitment to incorporating Adimab's innovative technologies in their endeavors to create impactful therapies that truly make a difference in patients’ lives. This interchange of ideas and technologies exemplifies the collaborative spirit that drives progressive health advancements.

The success of depemokimab caps off a series of achievements in Adimab's operations, where notable collaborators like Biogen, Lilly, Merck, Novo Nordisk, and Takeda are similarly harnessing the Adimab platform for their unique needs. Each of these partnerships empowers collaborators through committed training at Adimab and equips them to independently operate the proprietary technology with a distinctive focus that avoids overlapping outputs.

Adimab’s technology spans across various therapeutic areas, accommodating any biologic target and format. This flexibility is instrumental in guiding the journey from discovery through engineering while enabling the generation of multispecific products. Continuous support, including expert access to Adimab's scientific team, biannual technology summits, and regular updates to strains and tools, further enhances the collaborative experience.

Apart from depemokimab, numerous other commercial products utilizing Adimab’s technology have been achieving success across the globe. Examples include Innovent’s TYVYT® and SINTBILO®, IASO Bio’s FUCASO®, Invivyd's PEMGARDA™, and Sun Pharma's UNLOXCYT™. These products have not only seen commendable approvals in their respective categories but also reflect the range and scalability of Adimab’s expansive work.

As of now, the total number of clinical programs associated with Adimab has soared, crossing 90 collaborations that range from early-stage biotechnology to more established entities. Adimab remains focused solely on its partners, steering clear of internal product development, and allowing its collaborators to leverage its cutting-edge technologies.

About Adimab
Founded with a clear vision to serve its partners, Adimab offers a unique suite of antibody discovery and engineering technologies. Combining sophisticated methods from yeast and B cells along with innovative engineering, Adimab is striving to raise the bar in therapeutic antibody development. With a commitment to excellence, Adimab’s technologies serve as a catalyst for various pharmaceutical and biotechnology companies, helping them generate over 650 therapeutic programs, including a strong pipeline of clinical candidates.
For more information about Adimab and its innovative technologies, you can visit Adimab's website.